Recent IPO filing terms for ADARx Pharmaceuticals, targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17 and a concurrent AbbVie private placement of up to $100 million, anchor trader sentiment around the $1.5–2.25 billion closing market cap range. The siRNA developer’s Phase 3 lead asset in hereditary angioedema, substantial $335 million upfront collaboration with AbbVie, and extended cash runway into 2030 support the evenly distributed probabilities across multiple valuation buckets. Biotech IPO momentum, sector volatility, and post-listing trading dynamics on Nasdaq under ticker ADRX introduce uncertainty that keeps outcomes closely contested near 23–25% each.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于15亿美元-17.5亿美元 25%
25亿-30亿美元 24%
30亿美元以上 24%
17.5亿美元-20亿美元 23%
最新
最新
2026-09-25
低于15亿美元
12%
15亿美元-17.5亿美元
25%
17.5亿美元-20亿美元
23%
20亿-22.5亿美元
12%
22.5 亿美元-25 亿美元
12%
25亿-30亿美元
24%
30亿美元以上
24%
2026年11月前不上市
12%
15亿美元-17.5亿美元 25%
25亿-30亿美元 24%
30亿美元以上 24%
17.5亿美元-20亿美元 23%
最新
最新
2026-09-25
低于15亿美元
$0 交易量
12%
15亿美元-17.5亿美元
$40 交易量
25%
17.5亿美元-20亿美元
$0 交易量
23%
20亿-22.5亿美元
$0 交易量
12%
22.5 亿美元-25 亿美元
$0 交易量
12%
25亿-30亿美元
$0 交易量
24%
30亿美元以上
$0 交易量
24%
2026年11月前不上市
$0 交易量
12%
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent IPO filing terms for ADARx Pharmaceuticals, targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17 and a concurrent AbbVie private placement of up to $100 million, anchor trader sentiment around the $1.5–2.25 billion closing market cap range. The siRNA developer’s Phase 3 lead asset in hereditary angioedema, substantial $335 million upfront collaboration with AbbVie, and extended cash runway into 2030 support the evenly distributed probabilities across multiple valuation buckets. Biotech IPO momentum, sector volatility, and post-listing trading dynamics on Nasdaq under ticker ADRX introduce uncertainty that keeps outcomes closely contested near 23–25% each.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市场开放时间： Sep 23, 2026, 6:43 PM ET
交易量
$40结束日期
2026-09-25市场开放时间
Sep 23, 2026, 6:43 PM ETThis market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent IPO filing terms for ADARx Pharmaceuticals, targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17 and a concurrent AbbVie private placement of up to $100 million, anchor trader sentiment around the $1.5–2.25 billion closing market cap range. The siRNA developer’s Phase 3 lead asset in hereditary angioedema, substantial $335 million upfront collaboration with AbbVie, and extended cash runway into 2030 support the evenly distributed probabilities across multiple valuation buckets. Biotech IPO momentum, sector volatility, and post-listing trading dynamics on Nasdaq under ticker ADRX introduce uncertainty that keeps outcomes closely contested near 23–25% each.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$40结束日期
2026-09-25市场开放时间
Sep 23, 2026, 6:43 PM ETRecent IPO filing terms for ADARx Pharmaceuticals, targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17 and a concurrent AbbVie private placement of up to $100 million, anchor trader sentiment around the $1.5–2.25 billion closing market cap range. The siRNA developer’s Phase 3 lead asset in hereditary angioedema, substantial $335 million upfront collaboration with AbbVie, and extended cash runway into 2030 support the evenly distributed probabilities across multiple valuation buckets. Biotech IPO momentum, sector volatility, and post-listing trading dynamics on Nasdaq under ticker ADRX introduce uncertainty that keeps outcomes closely contested near 23–25% each.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题